Benign multiple sclerosis

S Glad1, H Nyland, K-M Myhr

  • 1Multiple Sclerosis National Competence Centre, Department of Neurology, Haukeland University Hospital, Bergen, Norway. solveig.bergloit.glad@helse-bergen.no

Insights

A small fraction of multiple sclerosis (MS) patients experience a benign disease course. Current definitions focus on physical ability, but non-motor symptoms like fatigue and pain significantly impact quality of life and should be included.

Area of Science:

  • Neurology
  • Clinical Medicine
  • Neuroimmunology

Background:

  • Multiple sclerosis (MS) is a chronic neurological disease.
  • A subset of MS patients exhibits a benign clinical course.
  • Current definitions of benign MS primarily assess motor function and ambulation.

Purpose of the Study:

  • To challenge the traditional definition of benign multiple sclerosis.
  • To advocate for the inclusion of non-motor symptoms in defining benign MS.
  • To highlight the impact of non-motor symptoms on patient disability.

Main Methods:

  • Review of existing literature on benign MS definitions.
  • Analysis of patient-reported outcomes focusing on non-motor symptoms.
  • Comparison of ambulatory status versus overall disability in MS patients.

Main Results:

  • Many fully ambulatory MS patients report significant disability from non-motor symptoms.
  • Fatigue, pain, depression, and cognitive dysfunction are prevalent.
  • These symptoms are often overlooked in traditional assessments of benign MS.

Conclusions:

  • The definition of benign MS requires re-evaluation.
  • Non-motor symptoms are critical indicators of disability in MS.
  • A comprehensive definition of benign MS must incorporate both motor and non-motor aspects.

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...